Systemic chemotherapy for operable breast cancer significantly decreases the risk of death. Docetaxel (Taxotere®, Aventis) has one of the highest response rates as a single agent in cancer, but ?de novo? and acquired resistance to this therapy are frequent. Investigators are now beginning to establish molecular profiles of these pathways, with the hope that this will lead to predictive biomarkers and novel therapies to overcome resistance to this highly efficacious agent and, at the same time, predict which women will be resistant to this therapeutic approach from the start, according to findings reported at the 39th Annual Meeting of the American Society of Clinical Oncology.
Go to Previous Page
Go to Next Page